New Delhi: Leading pharmaceutical company Cipla has sought permission to launch Favipiravir, an anti-viral drug, in India to fight against COVID-19.
Sources said the Council of Scientific and Industrial Research (CSIR) had developed an affordable process by using locally available chemicals to synthesise this Active Pharmaceutical Ingredient (API) and then transferred the technology to Cipla for mass production.
Favipiravir has shown promise in clinical trials for treatment of mild and moderate cases of COVID-19 patients, according to a statement by Cipla.
“Cipla has scaled up the process in its manufacturing facility and approached the Drug Controller General of India (DCGI) for permission to launch the product in India. Given that DCGI has given restricted emergency use for Favipiravir in the country, Cipla is now all set to launch the product to help COVID-19 patients,” the statement added.
CSIR Director General Shekhar C Mande said they are working with the industry in developing quick solutions and products for mitigation of COVID-19.
COVID Fight: Drug Watchdog Okays Favipiravir For Clinical Trials In India
Pune: Three people, including two toddlers, died on Monday when a dumper truck run over…
Lucknow: Three terrorists accused of lobbing a grenade at a police post in Punjab’s Gurdaspur…
Malkangiri: If things go as per plan, flight services between Odisha’s Malkangiri town and Visakhapatnam…
Bhubaneswar: Unidentified miscreants allegedly attacked a man and kidnapped his female friend in Maitri Vihar…
Balasore: A young man was allegedly beaten to death on the suspicion of having committed…
Mumbai: Bollywood celebrities have often had funny, at times bizarre experiences, mostly involving hero-worshipping, demanding fans.…
This website uses cookies.